7 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
leading cause of cancer-related death in the United States among both men and women. Based on the National Cancer Institute, Surveillance, Epidemiology
8-K
EX-99.1
CADL
Candel Therapeutics Inc
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
in the United States among both men and women. Based on the National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) database
8-K
EX-99.1
CADL
Candel Therapeutics Inc
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
is a highly lethal malignancy, and is the fourth leading cause of cancer-related death in the United States among both men and women. Based on the National
8-K
EX-99.1
CADL
Candel Therapeutics Inc
6 Nov 23
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:15am
of cancer-related death in the United States among both men and women. Based on the National Cancer Institute, Surveillance, Epidemiology and End Results
8-K
EX-99.1
t8rdsd0ij6fxsz0y
6 Dec 22
Regulation FD Disclosure
8:01am
- Prev
- 1
- Next